02/07/2012 - Lannett Reports Fiscal 2012 Second Quarter Financial Results
Lannett Company, Inc. (NYSE AMEX: LCI) today reported financial results for the fiscal 2012 second quarter and six months ended December 31, 2011.
Read More
Read More
01/31/2012 - Lannett Receives FDA Approval For ANDA Supplement For Phentermine HCL Capsules, 15 MG
Lannett Company, Inc. (NYSE AMEX: LCI), today announced that it has received approval from the U.S Food and Drug Administration (FDA) of its supplemental Abbreviated New Drug Application (ANDA) for Phentermine HCL Capsules, 15 mg.
Read More
Read More
01/30/2012 - Lannett To Report Fiscal 2012 Second-Quarter Financial Results And Host Conference Call On Tuesday, February 7
Lannett Company, Inc. (NYSE AMEX: LCI), a manufacture of generic pharmaceuticals, today announced that the company will release its fiscal 2012 second-quarter financial results on Tuesday, February 7, 2012 after the market closes.
Read More
Listen To Audio Webcast
Read More
Listen To Audio Webcast
01/30/2012 - Lannett Receives FDA Approval For Hydrochlorothiazide Capsules, 12.5 MG
Lannett Company, Inc. (NYSE AMEX: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrochlorothiazide Capsules, 12.5 mg.
Read More
Read More
01/04/2012 - Lannett Reaches Special Protocol Assessment Agreement With FDA For Cocaine HCL Phase III Trial
Lannett Company, Inc. (NYSE AMEX: LCI) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA), regarding the design of a Phase III study of the companys Cocaine HCl topical solution product, C-Topical.
Read More
Read More
12/12/2011 - Lannett Receives FDA Approval For Triamterene With Hydrochlorothiazide 37.5/25 MG Capsules
Lannett Company, Inc. (NYSE AMEX: LCI) today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules.
Read More
Read More
12/07/2011 - Lannett To Present At Oppenheimer 22nd Annual Healthcare Conference on December 14th
Lannett Company, Inc. (NYSE AMEX: LCI) today announced that the company will present at the Oppenheimer 22nd Annaul Healthcare Conference on Wednesday, December 14, 2011 at 11:25 a.m. ET at the Waldorf Astoria Hotel in New York City.
Read More
View the Webcast
News Archive
Recent Webcasts
Lannett To Report Fiscal 2012 Second-Quarter Financial Results And Host Conference Call On Tuesday, February 7 - 01/30/2012
Lannett To Present At Oppenheimer 22nd Annual Healthcare Conference on December 14th - 12/07/2011
Lannett To Present At Lazard Capital Markets 8th Annual Healthcare Conference On November 15th - 11/10/2011
Fiscal 2012 First-Quarter Financial Results Call - 10/27/2011
More Webcasts.
